---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: American hospital formulary service (AHFS), or other drug classification"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: American hospital formulary service (AHFS), or other drug classification. Topics: Pharmacologic class stated by the manufacturer, Proposed International Nonproprietary Name and class description, Nonproprietary name stem -citinib, and Nomenclature and drug dictionary entries in the FDA substance registration record. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/american-hospital-formulary-service-ahfs-or-other-drug-classification"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: American hospital formulary service (AHFS), or other drug classification

<a id="heading-2.1.2.4"></a>

## 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

### Pharmacologic class stated by the manufacturer

> “Envu is a potent, highly selective, allosteric TYK2 inhibitor.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.4-2"></a>

### Proposed International Nonproprietary Name and class description

| Field | Quoted record |
| --- | --- |
| Proposed INN (Latin) | “envudeucitinibum” |
| Class description | “Janus kinase inhibitor, anti-inflammatory” |
| Class description (French) | “inhibiteur de la kinase de Janus, anti-inflammatoire” |

Source: [World Health Organization proposed INN list 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl130.pdf)

<a id="topic-2.1.2.4-3"></a>

### Nonproprietary name stem -citinib

> “-citinib (see –tinib) Janus kinase inhibitors”

Source: [World Health Organization INN stem book (2024)](https://iris.who.int/server/api/core/bitstreams/a042b526-4e17-4f77-b437-42ce85e66219/content)

<a id="topic-2.1.2.4-4"></a>

### Nomenclature and drug dictionary entries in the FDA substance registration record

| Field | Quoted record |
| --- | --- |
| Substance type | “INGREDIENT SUBSTANCE” |
| Molecular formula | “C22H24N6O3” |
| United States Adopted Name synonym | “ENVUDEUCITINIB [USAN]” |
| WHO Drug Dictionary synonym | “ESK 001 [WHO-DD]” |

Source: [FDA UNII record for envudeucitinib](https://precision.fda.gov/uniisearch/srs/unii/KD2MDJ4GAB)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
